ADHD Therapeutics Market Size Worth USD 19740 Million by 2030 at 7.80% CAGR – Report by Market Research Future (MRFR)
01 mai 2023 09h00 HE
|
Market Research Future
New York, USA, May 01, 2023 (GLOBE NEWSWIRE) -- ADHD Therapeutics Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), ADHD Therapeutics...
MHA releases analysis of its online mental health screens taken in 2022; 6.3M global screenings taken, nearly 500k took new ADHD screen
01 mai 2023 06h30 HE
|
Mental Health America
Alexandria, VA, May 01, 2023 (GLOBE NEWSWIRE) -- More than 6.3 million people worldwide in 2022 took a mental health screening using the Mental Health America (MHA) Online Screening Program, a...
Cingulate to Participate in Benzinga All Live Access Event
14 avr. 2023 14h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
05 avr. 2023 08h30 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
04 avr. 2023 06h45 HE
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
New Study: Brain Training Improve Clinical and Cognitive Measures in Autism
27 mars 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, March 27, 2023 (GLOBE NEWSWIRE) -- New results from a study of brain training among people with autism spectrum disorder (ASD) show significant gains in clinical and cognitive...
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
13 mars 2023 06h45 HE
|
Cingulate Inc.
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in...
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
10 mars 2023 16h05 HE
|
Cingulate Inc.
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming...
NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
01 mars 2023 11h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
Applications for The Southport School’s Summer Programs Are Now Being Accepted
23 févr. 2023 16h33 HE
|
The Southport School Inc
SOUTHPORT, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- The Southport School (TSS), a private day school for neurodiverse children who have language-based learning differences and/or ADHD, today...